According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is A$97.9 Million. In 2024 the company made a revenue of A$0.28 Billion an increase over the revenue in the year 2023 that were of A$88.47 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.